(CW) Associate Director Value & Access Strategy Skeletal Conditions (Contract)

Who We Are

BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions.

Guided by our purpose to develop medicines that make a profound impact on people’s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options. More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions.

Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of BioMarin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world.

About Commercial

Be part of the worldwide infrastructure that gets our drugs to underserved patients around the world. Our global sales force solidifies BioMarin’s commercial presence in the United States and Europe and is rapidly growing in other regions, such as South America, EuMEA, and Asia-Pacific.

CONTRACT ROLE 100% remote position. Individual will need to travel to San Rafael quarterly for on-site meetings** Market Access Expertise: 7+ years in US Biotech/Pharma with deep experience in Payer Marketing, Patient Support Services, Pricing and Contracting Strategy, HEOR, and/or Launch Excellence.

This role is approximately 20 hours per week***

The Opportunity
We are seeking a US Market Access Launch Readiness Support Contractor to shape and deliver critical pre-launch market access deliverables for the Hypochondroplasia (HCH) launch, while ensuring strategic alignment across our broader skeletal conditions portfolio, including Achondroplasia (ACH).
This is a high-impact role demanding both strategic thinking and disciplined execution. As a key partner to the Senior Director, you will provide coordination oversight, cross-functional leadership, and direct execution accountability to secure Day-1 access for Voxzogo in the HCH indication.
Core Responsibilities
1. Launch Readiness Project Management
• Orchestrate the US Market Access HCH Launch workplan, driving milestone accountability across all workstreams — from payer readiness to Day-1 patient support services activation.
• Actively manage the launch critical path, identifying execution risks and leading mitigation efforts to protect Day-1 access commitments.
• Serve as the central coordination point across internal teams and external partners, ensuring workstream interdependencies are visible and managed proactively.
• Maintain a launch readiness dashboard to provide real-time visibility into workstream progress, milestone status, and risk flags, enabling rapid decision-making.

2. Payer Value & Asset Development
• Support the development and refinement of the Pre-Approval Payer Value Deck, synthesizing complex clinical and economic evidence into a clear, compelling narrative for payer engagements to ensure payer readiness.
• Manage the end-to-end MMRC/PRB submission and review process for all payer-facing HCH assets.
• Support strategic material development, logistical oversight, and insight synthesis for the upcoming Payer Ad Board in collaboration with external vendors and internal stakeholders.

3. Launch Readiness Pull-through
• Oversee operational alignment across V&A Strategy, Patient Support Services, Pricing & Contracting, and Distribution Channels team to ensure frictionless access for providers and patients upon product launch.
• Oversee pull-through readiness across payers, providers, hubs, specialty pharmacies, and distributors — ensuring no gaps at the point of patient access.
• Serve as a hands-on strategic resource for ad-hoc initiatives as they emerge across the launch lifecycle, flexing capacity to address high-priority needs across market access workstreams in real time.

Qualifications & Experience
• Market Access Expertise: 7+ years in US Biotech/Pharma with deep experience in Payer Marketing, Patient Support Services, Pricing and Contracting Strategy, HEOR, and/or Launch Excellence.
• Portfolio Complexity: Proven ability to manage access strategies for multiple indications or products simultaneously
• Launch Execution: Direct experience managing the 'critical window' of pre-approval deliverables and Day-1 readiness.
• Cross-functional Leadership: Ability to collaborate and contextualize trade-offs with medical, legal, and regulatory for MMRC/PRB reviews.
• Communication: Exceptional ability to translate clinical and economic data into payer value communications and strategy documents.
• Vendor Management: Experience managing external agencies and vendors end-to-end — including scoping, contracting, directing deliverables, and ensuring on-time, on-strategy outputs.
• Rare Disease / Specialty Experience: Familiarity with rare or ultra-rare disease access dynamics is preferred.
The Impact
In this role, you will be the primary driver of the execution steps that define our market success. By closing the gap on critical pre-approval deliverables, you ensure our breakthrough therapy is positioned for immediate uptake and long-term success.

Note: This description is not intended to be all-inclusive, or a limitation of the duties of the position. It is intended to describe the general nature of the job that may include other duties as assumed or assigned.

Equal Opportunity Employer/Veterans/Disabled

An Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.